FindTrial
Sign In

Assessment of effect of Sugammadex reversal of Rocuronium neuromuscular blockade on Motor Evoked Potential Monitoring during Spine surgery

Assessment of impact of Sugammadex reversal of Rocuronium blockade on Transcranial Motor Evoked Potential Monitoring during Spine surgery-A prospective randomized controlled trial - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/089306
Enrollment
90
Registered
2025-06-23
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G988- Other disorders of nervous system

Interventions

Intervention1: Rocuronium: 0.6 milligram per kilogram body weight Intervention2: Nil: Nil Control Intervention1: Cistarcurium: 0.2 milligram per kilogram body weight

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age between 18-65 years Americal Society of Anesthesiologists physical status I-II No preoperative upper limb sensory or motor neurological deficits

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Amplitude of Transcranial Motor evoked potential following reversal of rocuronium with sugammadexTimepoint: 30 minutes after induction of anesthesia and 5, 10,15 ,20 and 30 minutes after dural opening/laminectomy—

Secondary

MeasureTime frame
comparision with amplitude of transcranial motor evoked potential following administration of cisatracurium and rocuronium infusion time taken for re -appearance of second twitch of train of four counts in both groupsTimepoint: amplitude and latency of trans cranial Motor evoked potential 5,10,20,30 and 60 minutes—

Countries

India

Contacts

Public ContactDr Sapna Suresh

Aster Medicity

sapna.gogi@gmail.com8086177209

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026